How SBRT Has Evolved Over the Decades to Manage Kidney Cancer
December 03, 2022

An expert from the University of Texas Southwestern Medical Center in Dallas gives an overview of the multimodal use of stereotactic radiation for the treatment of patients with metastatic kidney cancer.

FDA Grants Fast Track Designation to Novel HSF1 Pathway Inhibitor NXP800 for Ovarian Cancer
December 03, 2022

The first-in-class Heat Shock Factor 1 pathway inhibitor NXP800, the subject of an ongoing phase 1 dose-escalation study, has been granted a Fast Track designation for the treatment of platinum-resistant ovarian cancer by the FDA.

Review Finds No Association Between Higher BMI and Decreased Kidney Function Following Partial Nephrectomy for Kidney Cancer
December 02, 2022

According to a retrospective chart review, there was no significant correlation between BMI and changes in renal function among patients who underwent partial nephrectomy for the treatment of kidney cancer.

Follow-Up Data Show Tazemetostat Remains Safe, Elicits Benefit in Patients With Prostate Cancer
December 02, 2022

At a median follow-up of 17.4 months, half of the enrolled patients with metastatic castration-resistant prostate cancer experienced a decrease in PSA level from baseline following treatment with tazemetostat in combination with abiraterone acetate or enzalutamide.

Neoadjuvant Axitinib May Reduce Size of Complex Kidney Masses Enough to Permit Partial Nephrectomy in Cases of Kidney Cancer
December 02, 2022

The findings, according to the lead study author from UC San Diego School of Medicine, are a proof of concept and need to be confirmed in a phase 2 trial.

Adding Blue Light Cystoscopy to Standard White Light Decreases Tumor Recurrence in a Type of Bladder Cancer
December 02, 2022

Findings from an interim analysis of data show that the addition of blue light cystoscopy to conventional white light significantly improved clinical outcomes in a group of patients with non–muscle-invasive bladder cancer.

Novel PSMA-TRT-based Triplet Regimen Appears Effective in Prostate Cancer
December 02, 2022

All patients with chemo-naïve metastatic castration-resistant prostate cancer experienced PSA decline, and half the cohort experienced a PSA decline greater than 50% after treatment with a novel PSMA-targeted radionuclide therapy.

Novel PET Imaging Agent 18F-rHPSMA-7.3 Proves Clinically Useful Prior to Surgery in Newly Diagnosed Prostate Cancer
December 02, 2022

Patients with newly diagnosed prostate cancer benefitted from 18F-rHPSMA-7.3 PET when used prior to surgery.

Stereotactic Radiation Offers ‘Another Modality’ for the Management of Metastatic Kidney Cancer, Says Expert
December 02, 2022

An expert from the University of Texas Southwestern Medical Center in Dallas emphasized that stereotactic radiation provides oncologists with an alternative modality for treating patients with kidney cancer for whom standard ablative surgery.

FDA Approves Olutasidenib for Acute Myeloid Leukemia Subtype
December 01, 2022

The FDA’s approval of oral olutasidenib provides adults with relapsed or refractory acute myeloid leukemia harboring a susceptible IDH1 mutation a new treatment option.